Novo Nordisk Annual Report 2021
Contents Introducing Novo Nordisk
Strategic Aspirations
Key risks
Management
Consolidated statements
Additional information.
Novo Nordisk Annual Report 2021
31
سے
Delivering on our ambitions even during these exceptional
times has required our commercial teams to rapidly adopt
new ways of doing business and increase their use of digital
tools. This shift was necessitated by the pandemic, but it
has now become standard practice across the organisation.
Today, we are embracing virtual customer interactions in
multiple settings and developing new digital competences as
we apply a market-fit approach to our operations.
A watershed year in obesity therapy
Obesity was an important stand-out in 2021, both for
patients and for our business. The US launch of WegovyⓇ
in June 2021 marked the start of a new era in obesity care
and underscored the value that our innovations can bring to
society. The exceptional demand for the therapy - exceeding
all expectations - was testament to the high unmet need
among people living with the disease, while the fact that our
medicine helps patients achieve unprecedented weight loss,
fuelled extensive media attention. Acceptance by payers
was also highly encouraging, with US commercial formulary
access now around 73%.
As a result of this exceptional interest, initial demand for
WegovyⓇ exceeded supply, requiring careful management
to ensure continuity of care for individual patients who had
already started treatment. Despite increasing production
efforts, additional supply chain challenges encountered
towards the end of 2021 mean we do not expect to be able
to meet demand in the US until the second half of 2022
- with relatively few new patients expected to be able to
initiate treatment as a result.
understanding of the need to address obesity is winning
healthcare system reimbursement in select sub-populations
across a growing number of markets, creating a solid platform
for the increasing uptake of anti-obesity medications.
We are the global leader in obesity treatment, with a value
market share of 77.8% of branded prescription sales, and there
is substantial scope for further growth in the years ahead. There
are currently around 650 million people living with obesity, and
in 10 years the total is likely to be closer to 1 billion.
Diabetes value market share
%
55
GLP-1
Insulin - Diabetes
52.7%
50.4%
50
47.5%
45
44.5%
44.3%
43.8%
40
35
29.3%
28.6%
30.1%
30
25
Kara Richadrson Whitely lives with obesity
in the US. She has hiked Mount Kilimanjaro
three times
20
2019
Outside the US, our first-generation obesity product
SaxendaⓇ has now been launched in 62 countries. Better
Source: IQVIA data
2020
2021View entire presentation